Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.210
+0.155 (3.82%)
Jul 30, 2026, 1:45 PM EDT - Market open
Immuneering Employees
Immuneering had 55 employees as of March 31, 2026. The number of employees increased by 2 or 3.77% since the number was last reported on December 31, 2025.
Employees
55
Change
2
Growth
3.77%
Revenue / Employee
n/a
Profits / Employee
-$989,812
Market Cap
272.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 55 | 2 | 3.77% |
| Dec 31, 2025 | 53 | -13 | -19.70% |
| Dec 31, 2024 | 66 | -2 | -2.94% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Fate Therapeutics | 161 |
| Foghorn Therapeutics | 106 |
| OmniAb | 89 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| ALX Oncology Holdings | 43 |
| Eledon Pharmaceuticals | 33 |
IMRX News
- 8 days ago - Immuneering publishes preclinical data on atebimetinib in Cancer Research - TheFly
- 8 days ago - Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition - GlobeNewsWire
- 12 days ago - Immuneering Corporation Announces Grants of Inducement Awards - GlobeNewsWire
- 22 days ago - Immuneering initiated with an Overweight at Cantor Fitzgerald - TheFly
- 6 weeks ago - Immuneering appoints Andrew Gengos as CFO - TheFly
- 6 weeks ago - Immuneering Appoints Andrew Gengos as Chief Financial Officer - GlobeNewsWire
- 7 weeks ago - Immuneering Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - GlobeNewsWire